Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

April 13, 2018: By Jon Swedien

AbbVie has struck a deal with Samsung Bioepis and Biogen that will allow the partners to sell Imraldi—a biosimilar referencing Humira (adalimumab)—in Europe beginning in 2018, and, in exchange, they have agreed to drop a lawsuit challenging Humira’s patent, the companies announced April 5.

Humira is indicated in Europe for chronic non-infectious anterior uveitis.

Under terms of the agreement, AbbVie said it will grant patent licenses for the use and sale of Imraldi in Europe on a country-by-country basis, and the license period will begin in most European Union countries Oct. 16, 2018.

Samsung Bioepis and Biogen will make royalty payments to AbbVie, the companies said.

AbbVie also disclosed the deal will allow Samsung Bioepis to sell its biosimilar in the US beginning June 30, 2023.

The precise terms of the agreements are confidential, the companies said.

In 2017, AbbVie struck a deal with Amgen allowing it to sell its Humira biosimilar in the US beginning in January 2023 in exchange for royalty payments to AbbVie and dropping a patent challenge to Humira.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023